학술논문
Clinical outcomes in individuals hospitalized with SARS-CoV-2 Delta variant (B.1.617.2) who had been vaccinated with Covishield (ChAdOx1) and Covaxin (BBV-152).
Document Type
Academic Journal
Author
Munigela A; AIG Hospitals, Internal Medicine, Gachibowli, Hyderabad, Telangana, India.; Sowpati DT; CSIR - Centre for Cellular and Molecular Biology, Habsiguda, Hyderabad, Telangana, India.; M S; Asian Healthcare Foundation, Gachibowli, Hyderabad, Telangana, India.; Banu S; CSIR - Centre for Cellular and Molecular Biology, Habsiguda, Hyderabad, Telangana, India.; Academy of Scientific and Industrial Research, Ghaziabad, India.; Siva AB; CSIR - Centre for Cellular and Molecular Biology, Habsiguda, Hyderabad, Telangana, India.; V JK; AIG Hospitals, Internal Medicine, Gachibowli, Hyderabad, Telangana, India.; Nutalapati C; AIG Hospitals, Internal Medicine, Gachibowli, Hyderabad, Telangana, India.; Vishnubhotla R; Asian Healthcare Foundation, Gachibowli, Hyderabad, Telangana, India.; Kulkarni A; AIG Hospitals, Internal Medicine, Gachibowli, Hyderabad, Telangana, India.; Mukherjee P; CSIR - Centre for Cellular and Molecular Biology, Habsiguda, Hyderabad, Telangana, India.; Zaveri L; CSIR - Centre for Cellular and Molecular Biology, Habsiguda, Hyderabad, Telangana, India.; Rao GV; AIG Hospitals, Internal Medicine, Gachibowli, Hyderabad, Telangana, India.; Tallapaka KB; CSIR - Centre for Cellular and Molecular Biology, Habsiguda, Hyderabad, Telangana, India.; Nageshwar Reddy D; AIG Hospitals, Internal Medicine, Gachibowli, Hyderabad, Telangana, India.
Source
Publisher: Elsevier Ltd Country of Publication: England NLM ID: 9918418183106676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2772-7076 (Electronic) Linking ISSN: 27727076 NLM ISO Abbreviation: IJID Reg Subsets: PubMed not MEDLINE
Subject
Language
English
Abstract
Background: Covishield (ChAdOx) and Covaxin (BBV-152) are the mainstream vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) used in India and a few other countries.
Objective: To assess the clinical outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19) who had been vaccinated with either Covishield or Covaxin.
Methods: This prospective, single-centre, observational cohort study of 1160 patients hospitalized with COVID-19 was conducted between April and June 2021. Severity of disease at admission and during hospitalization, requirement for intensive care unit (ICU) admission and ventilatory support, inflammatory markers (C-reactive protein, ferritin, lactate dehydrogenase, D-dimer), neutralizing antibody levels and mortality were assessed in vaccinated and unvaccinated patients.
Results: More than 90% of patients in this study harboured the Delta variant (Pango lineage B.1.617.2) of SARS-CoV-2. Severity of disease at admission and during hospitalization (3.44% vs 7.51%; P =0.0032) and requirement for ICU admission and ventilatory support (2.83% vs 5.86%; P =0.0154) were significantly lower in vaccinated patients compared with unvaccinated patients. Vaccinated patients also had significantly ( P <0.0001) higher antibody levels and lower inflammatory marker levels compared with unvaccinated patients. A subset of vaccinated, deceased patients mounted minimal antibody response ['non-responders': 4.53 (standard deviation 1.40) AU/mL].
Conclusion: These results demonstrate the effectiveness of Covishield and Covaxin against severe disease in patients hospitalized with COVID-19 with breakthrough infections caused by the Delta variant. Strategies targeting non-responders are desirable to minimize morbidity and mortality.
Competing Interests: None declared.
(© 2022 The Authors.)
Objective: To assess the clinical outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19) who had been vaccinated with either Covishield or Covaxin.
Methods: This prospective, single-centre, observational cohort study of 1160 patients hospitalized with COVID-19 was conducted between April and June 2021. Severity of disease at admission and during hospitalization, requirement for intensive care unit (ICU) admission and ventilatory support, inflammatory markers (C-reactive protein, ferritin, lactate dehydrogenase, D-dimer), neutralizing antibody levels and mortality were assessed in vaccinated and unvaccinated patients.
Results: More than 90% of patients in this study harboured the Delta variant (Pango lineage B.1.617.2) of SARS-CoV-2. Severity of disease at admission and during hospitalization (3.44% vs 7.51%; P =0.0032) and requirement for ICU admission and ventilatory support (2.83% vs 5.86%; P =0.0154) were significantly lower in vaccinated patients compared with unvaccinated patients. Vaccinated patients also had significantly ( P <0.0001) higher antibody levels and lower inflammatory marker levels compared with unvaccinated patients. A subset of vaccinated, deceased patients mounted minimal antibody response ['non-responders': 4.53 (standard deviation 1.40) AU/mL].
Conclusion: These results demonstrate the effectiveness of Covishield and Covaxin against severe disease in patients hospitalized with COVID-19 with breakthrough infections caused by the Delta variant. Strategies targeting non-responders are desirable to minimize morbidity and mortality.
Competing Interests: None declared.
(© 2022 The Authors.)